Patents by Inventor Zhaoming Xiong

Zhaoming Xiong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210393599
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: December 23, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Kathleen J. Murauski
  • Publication number: 20210205277
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: July 8, 2021
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Zhaoming Xiong, Michael J. Dart
  • Patent number: 10954202
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: March 23, 2021
    Assignee: AbbVie Inc.
    Inventors: Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
  • Patent number: 10954215
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Robert Owen Hughes, Xiang Li, Peter Allen Nemoto, Lana Louise Smith Keenan, Lifen Wu, Zhaoming Xiong
  • Publication number: 20210009542
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Inventors: Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
  • Publication number: 20200361941
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 19, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Brian S. Brown, Kathleen J. Murauski
  • Publication number: 20200347033
    Abstract: Provided herein are compounds of Formula (I) or Formula (II), compositions, and methods there of useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Yunsong Tong, Xiangdong Xu, Lei Shi, SeungWon Chung, Zhaoming Xiong, Kathleen J. Murauski, Qingwei I. Zhang, Brian S. Brown, Michael J. Dart
  • Publication number: 20200071298
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also en-compasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: December 12, 2017
    Publication date: March 5, 2020
    Inventors: Robert Owen HUGHES, Xiang LI, Peter Allen NEMOTO, Lana Louise SMITH KEENAN, Lifen WU, Zhaoming XIONG
  • Patent number: 10570118
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Darren Todd DiSalvo, Wang Mao, Fariba Soleymanzadeh, John A. Westbrook, Zhaoming Xiong
  • Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Publication number: 20190023686
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Darren Todd DISALVO, Wang MAO, Fariba SOLEYMANZADEH, John A. WESTBROOK, Zhaoming XIONG
  • Patent number: 10131642
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Balestra, Jörg M. Bentzien, Jennifer Burke, Derek Cogan, Xin Guo, Keith R. Hornberger, John Lord, Kenneth M. Meyers, Zhaoming Xiong, Maolin Yu, Zhonghua Zhang
  • Publication number: 20180312475
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: January 28, 2016
    Publication date: November 1, 2018
    Inventors: Michael BALESTRA, Jörg M. BENTZIEN, Jennifer BURKE, Derek COGAN, Xin GUO, Keith R. HORNBERGER, John LORD, Kenneth M. MEYERS, Zhaoming XIONG, Maolin YU, Zhonghua ZHANG
  • Publication number: 20180298005
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: September 28, 2016
    Publication date: October 18, 2018
    Inventors: Steven Richard BRUNETTE, Johanna CSENGERY, Robert Owen HUGHES, Xiang LI, Robert SIBLEY, Michael Robert TURNER, Zhaoming XIONG
  • Patent number: 8785489
    Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 22, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Bennett Farmer, Neil Alexander Farrow, Donghong Amy Gao, Alexander Heim-Riether, Lana Louise Smith Keenan, Ingo Andreas Mugge, Steven John Taylor, Zhaoming Xiong, Yang Yu, Qiang Zhang
  • Patent number: 8729114
    Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: May 20, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael J. Burke, Derek Cogan, Donghong Amy Gao, Alexander Heim-Riether, Eugene Richard Hickey, Matthew Russell Netherton, Philip Dean Ramsden, David Charles Thompson, Zhaoming Xiong
  • Patent number: 8637550
    Abstract: Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Neil Alexander Farrow, Donghong Amy Gao, Alexander Heim-Riether, Sabine Schlyer, Lana Louise Smith Keenan, Steven John Taylor, Bernd Wellenzohn, Dieter Wiedenmayer, Zhaoming Xiong, Qiang Zhang
  • Patent number: 8552205
    Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-?]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: October 8, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Antonio Jose del Moral Barbosa, Jr., Joerg Martin Bentzien, Steven Richard Brunette, Zhidong Chen, Derek Cogan, Donghong A. Gao, Alexander Heim-Riether, Joshua Courtney Horan, Jennifer A. Kowalski, Michael David Lawlor, Rene Marc Lemieux, Weimin Liu, Bryan McKibben, Craig Andrew Miller, Neil Moss, Matt Aaron Tschantz, Zhaoming Xiong, Hui Yu, Yang Yu
  • Publication number: 20130158018
    Abstract: Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same.
    Type: Application
    Filed: March 2, 2011
    Publication date: June 20, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Michael J. Burke, Derek Cogan, Donghong Amy Gao, Alexander Heim-Riether, Eugene Richard Hickey, Matthew Russell Netherton, Philip Dean Ramsden, David Charles Thompson, Zhaoming Xiong
  • Patent number: 8299123
    Abstract: The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: October 30, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kaka Dey, Donghong Amy Gao, Daniel R. Goldberg, Alexander Heim-Riether, John Edward Mangette, Ingo Andreas Mugge, Roger John Snow, Alan David Swinamer, Jiang-Ping Wu, Zhaoming Xiong, Yu Yang